63876-32-4

Basic information

• Product Name: 4-(BENZYL-ETHOXYCARBONYLMETHYL-AMINO)-BUTYRIC ACID ETHYL ESTER
• Synonyms: 4-(BENZYL-ETHOXYCARBONYLMETHYL-AMINO)-BUTYRIC ACID ETHYL ESTER;ethyl 4-[benzyl(2-ethoxy-2-oxoethyl)amino]butyrate;4-[(2-Ethoxy-2-oxoethyl)(phenylmethyl)amino]butanoic acid ethyl ester;Butanoic acid, 4-[(2-ethoxy-2-oxoethyl)(phenylMethyl)aMino]-, ethyl ester
• CAS NO: 63876-32-4
• Molecular Formula: C₁₇H₂₅NO₄
• Molecular Weight: 307.3847
• EINECS: 264-542-1
• Mol File: 63876-32-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 395.8°Cat760mmHg
• Flash Point: 193.2°C
• Appearance: /
• Density: 1.078g/cm³
• Vapor Pressure: 1.79E-06mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(BENZYL-ETHOXYCARBONYLMETHYL-AMINO)-BUTYRIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(BENZYL-ETHOXYCARBONYLMETHYL-AMINO)-BUTYRIC ACID ETHYL ESTER(63876-32-4)
• EPA Substance Registry System: 4-(BENZYL-ETHOXYCARBONYLMETHYL-AMINO)-BUTYRIC ACID ETHYL ESTER(63876-32-4)

Safety Data

• Hazardous Substances Data: 63876-32-4(Hazardous Substances Data)

Usage

General Description

4-(Benzyl-ethoxycarbonylmethyl-amino)-butyric acid ethyl ester is a synthetic compound with potential application in biomedical research and pharmaceutical development. It contains a benzyl group, an ethoxycarbonylmethyl group, an amino group, and a butyric acid group, and is esterified with an ethyl group. This chemical may have potential as a prodrug, which is a compound that is inactive until it is metabolized in the body to release the active drug. Further research is needed to fully understand the potential uses and effects of this compound.

InChI:InChI=1/C17H25NO4/c1-3-21-16(19)11-8-12-18(14-17(20)22-4-2)13-15-9-6-5-7-10-15/h5-7,9-10H,3-4,8,11-14H2,1-2H3

Upstream product

• 3153-36-4 4-chloro-butyric acid ethyl ester 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 1212-58-4 4-(benzylamino)butyric acid ethyl ester hydrochloride 
• 105-36-2 ethyl bromoacetate 
• 100-46-9 benzylamine 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 26735-10-4 4-(benzylamino)butanoic acid 
• 79-11-8 chloroacetic acid 

Downstream Products

• 62458-96-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one 
• 1142188-60-0 4-hydroxy-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester 
• 1053656-57-7 4-chloro-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester 
• 109-00-2 3-HYDROXYPYRIDINE 
• 312625-46-0 (SR)-1,4-dibenzyl-3-oxo-piperidine-4-carboxylic acid ethyl ester 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 312625-23-3 (3S,4S)-4-benzyl-1-[2-(4-hydroxybenzenesulfonyl)ethyl]piperidin-3-ol 
• 312625-28-8 (3S,4S)-4-benzylpiperidin-3-ol 
• 857385-77-4 3-(4-ethoxy-phenyl)-1-benzyl-piperidin-3-ol 
• 58879-07-5 N-benzyl-3-hydroxy-3-phenylpiperidine 
• 40114-49-6 1-benzyl-3-piperidone 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 

Relevant articles and documents

Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride

The invention provides a preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride, and the method comprises the following steps: (1) preparing an intermediate 2: dissolving N-benzyl glycine ethyl ester in an organic solvent, adding 4-halogenated ethyl butyrate and alkali, and reacting to obtain N-benzyl glycine ethyl ester; (2) dissolving the intermediate 2 in anorganic solvent, reacting with alkali, adjusting the pH value to 7-8 after the reaction is finished, adding water for washing, adjusting the pH value of an organic layer to 1-2, and separating out crystals to obtain a crude product; and (3) dissolving the crude product in water, adding alkali to adjust the pH value to 7-8, adding an organic solvent to extract, washing, adjusting the pH value of anorganic layer to 1-2, and crystallizing to obtain the product. The method is simple in process operation, high in product yield, high in purity and easy for industrial production.

With the biological activity of 5, 6, 7, 8 - tetrahydro-pyrido [3, 4 - d] pyrimidine compound and its preparation method and application (by machine translation)

The invention discloses a has biological activity of 5, 6, 7, 8 - tetrahydro-pyrido [3, 4 - d] pyrimidine compound and its preparation method and application, which belongs to the with anti-tumor activity to the technical field of the synthesis of the compounds. The technical scheme of the present invention is to point: has biological activity of 5, 6, 7, 8 - tetrahydro-pyrido [3, 4 - d] pyrimidine compound, has the following structure:, wherein R1 For the ethyl carboxylic acid ester, ethylamine methyl, formyl methyl amine, dimethyl amino formyl, pyridine - 3 - methylene amino formyl, piperidine a acyl or anilino formyl, R2 For hydrogen or phenmethyl. The invention also discloses the has biological activity of 5, 6, 7, 8 - tetrahydro-pyrido [3, 4 - d] pyrimidine compound of preparation method and the preparation of anti-mammary tumor application of the medicament. The process of preparing the process is simple, easy to control, the target product high yield and good repeatability, prepared with anti-tumor activity of 5, 6, 7, 8 - tetrahydro-pyrido [3, 4 - d] pyrimidine compounds are all on breast cancer cell MCF - 7 has definite inhibitory effect. (by machine translation)

ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF

Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like.